MUFG Securities EMEA plc raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 375.4% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 498,580 shares of the biopharmaceutical company’s stock after acquiring an additional 393,700 shares during the quarter. Gilead Sciences makes up 0.8% of MUFG Securities EMEA plc’s holdings, making the stock its 21st largest holding. MUFG Securities EMEA plc’s holdings in Gilead Sciences were worth $35,718,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in the business. Welch Investments LLC bought a new position in shares of Gilead Sciences during the 3rd quarter worth $108,000. Wealthcare Advisory Partners LLC bought a new position in shares of Gilead Sciences during the 3rd quarter worth $133,000. Horan Capital Advisors LLC. bought a new position in shares of Gilead Sciences during the 3rd quarter worth $144,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Gilead Sciences during the 2nd quarter worth $147,000. Finally, Hanson & Doremus Investment Management grew its position in shares of Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 1,613 shares in the last quarter. 77.96% of the stock is currently owned by institutional investors.
Shares of Gilead Sciences, Inc. (GILD) opened at $79.74 on Friday. The company has a quick ratio of 2.67, a current ratio of 2.74 and a debt-to-equity ratio of 1.53. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $89.54. The company has a market capitalization of $104,155.56, a PE ratio of 22.91, a price-to-earnings-growth ratio of -1.83 and a beta of 1.24.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, beating analysts’ consensus estimates of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The company had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $5.71 billion. During the same period last year, the business posted $2.70 earnings per share. The firm’s revenue was down 18.7% compared to the same quarter last year. equities research analysts predict that Gilead Sciences, Inc. will post 6.21 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be paid a $0.57 dividend. The ex-dividend date of this dividend is Thursday, March 15th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a yield of 2.86%. Gilead Sciences’s dividend payout ratio (DPR) is 65.52%.
In other Gilead Sciences news, Chairman John C. Martin sold 50,000 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $83.56, for a total value of $4,178,000.00. Following the completion of the sale, the chairman now directly owns 3,046,766 shares in the company, valued at $254,587,766.96. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Robin L. Washington sold 5,000 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $80.31, for a total value of $401,550.00. Following the completion of the sale, the chief financial officer now owns 23,749 shares of the company’s stock, valued at $1,907,282.19. The disclosure for this sale can be found here. Over the last quarter, insiders sold 430,268 shares of company stock valued at $34,074,395. 1.30% of the stock is currently owned by company insiders.
A number of research firms have recently issued reports on GILD. Barclays reissued an “overweight” rating and set a $95.00 price target (up previously from $90.00) on shares of Gilead Sciences in a research report on Tuesday, March 6th. BidaskClub downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, March 3rd. Zacks Investment Research raised Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, February 28th. Mizuho set a $95.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research report on Monday, February 5th. Finally, Leerink Swann reissued a “market perform” rating and set a $80.00 price target (down previously from $83.00) on shares of Gilead Sciences in a research report on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. Gilead Sciences presently has a consensus rating of “Buy” and an average price target of $88.61.
TRADEMARK VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Shares Bought by MUFG Securities EMEA plc” was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://ledgergazette.com/2018/03/17/gilead-sciences-inc-gild-shares-bought-by-mufg-securities-emea-plc.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.